Seres Therapeutics (MCRB) Misses Q3 EPS by 6c

Seres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of ($0.38), $0.06 worse than the analyst estimate of ($0.32).

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral
• RBC Capital Reiterates Outperform Rating on Aviva PLC (AV:LN) (AVVIY)